San Diego-based Lithera says it has secured an additional $8 million to close its Series C round of financing that began more than a year ago. The aesthetic biotech, founded in 2007, has been advancing FDA-registered drugs already approved for use in other indications. Lithera’s lead drug is intended for use as an injectable drug for reducing belly fat. The company said last year that it expected to extend the second tranche of the round and might raise as much as $25 million.
Help employers find you! Check out all the jobs and post your resume.
